– Former Roche head of neuroimmunology strengthens Rewind’s expertise in neuroimmunology and neurodegeneration

Leuven, Belgium, October 19, 2022 — Rewind Therapeuticsa company developing first-in-class treatments for demyelination-associated diseases, today announced that Irene Knuesel, PhD, PD, has been appointed as the company’s Chief Scientific Officer.

Irene Knuesel brings many years of experience in CNS research, drug discovery and development. She is also the founder of Scienza Consulting GmbH, an independent science consulting company. Among other things, she brings six years of experience in defining and implementing discovery strategies in neuroimmunology and neurodegeneration at F. Hoffmann-La Roche, where in her last position as Head of the Neuroimmunology and Neurodegeneration Section she was responsible for 11 research laboratory leaders with a focus on neuroimmunology and neurodegenerative mechanisms underlying disease and disability progression in multiple sclerosis, Alzheimer’s and Parkinson’s. Prior to her career at F. Hoffman-La Roche, she held numerous academic positions in the field of neurobiology at the University of Zurich, the California Institute of Technology, Pasadena, CA (USA) and the Swiss Federal Institute of Technology (Zurich, Switzerland). . Irene Knuesel holds a PhD in Molecular Neuroscience from the University of Zurich and a PhD from the Medical Faculty of the University of Zurich.

“We warmly welcome Irene as our new CSO and are delighted that she is joining Rewind,” said Anja Harmeier, Chief Executive Officer at Rewind Therapeutics. “It is a great pleasure to work with Irene as she brings outstanding industry expertise in drug discovery and the development of novel neurotherapeutics. Our goal is to evolve into a clinical-stage portfolio company and we know that Irene will play a significant role in the evolution of Rewind. “

“Rewind Therapeutics has built a great team and deep expertise in remyelination,” said Irene Knuesel, Chief Scientific Officer at…